• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗抑郁药噻奈普汀在老年人稳态时的药代动力学

Pharmacokinetics of the antidepressant tianeptine at steady state in the elderly.

作者信息

Demotes-Mainard F, Galley P, Manciet G, Vinson G, Salvadori C

机构信息

Centre de Pharmacologie Clinique, Université de Bordeaux II, France.

出版信息

J Clin Pharmacol. 1991 Feb;31(2):174-8. doi: 10.1002/j.1552-4604.1991.tb03703.x.

DOI:10.1002/j.1552-4604.1991.tb03703.x
PMID:2010563
Abstract

The pharmacokinetics of tianeptine, an antidepressant with an original serotoninergic neurochemical action, was investigated in elderly patients. Kinetic profiles were developed in 12 elderly patients (age range: 72-81 yr) after single (12.5 mg) dose and multiple oral dosages (12.5 mg tid for 17 days). Multiple dosing of tianeptine was well tolerated; no accumulation of the unchanged drug was observed. Tianeptine and its MC5 metabolite (C5 acid analogue of tianeptine) reached maximum plasma levels after 1.81 +/- .99 and 2.96 +/- 1.44 hr, respectively, with values of 353 +/- 198 and 81 +/- 20 ng/mL, respectively, after a single dose and of 405 +/- 202 and 175 +/- 85 ng/mL, respectively, after multiple dosing. Minimum plasma concentrations of tianeptine were about half those of its MC5 metabolite (68 +/- 41 and 121 +/- 64 ng/mL-1 on day 5), and for each compound, they were not statistically different from day 5 to day 18 of the chronic administration. This finding is compatible with the terminal half-lives that were observed after the single dose that was 2.8 +/- .9 hr for tianeptine and 12.3 +/- 7 hr for the MC5 metabolite. For both compounds, the area-under-the-plasma levels time curve at steady state was as predicted from the initial single dose that showed no deviation from linearity with time. The kinetics of tianeptine in elderly patients were similar to those reported for young adults. However, MC5 metabolite plasma levels were higher in elderly patients than in younger patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对具有独特5-羟色胺能神经化学作用的抗抑郁药噻奈普汀在老年患者中的药代动力学进行了研究。在12名老年患者(年龄范围:72 - 81岁)中,分别给予单剂量(12.5毫克)和多次口服剂量(12.5毫克,每日三次,共17天)后,绘制了药代动力学曲线。噻奈普汀多次给药耐受性良好;未观察到原形药物的蓄积。噻奈普汀及其MC5代谢物(噻奈普汀的C5酸类似物)分别在1.81±0.99小时和2.96±1.44小时后达到血浆最高水平,单剂量给药后的值分别为353±198纳克/毫升和81±20纳克/毫升,多次给药后分别为405±202纳克/毫升和175±85纳克/毫升。噻奈普汀的血浆最低浓度约为其MC5代谢物的一半(第5天分别为68±41和121±64纳克/毫升),对于每种化合物,在长期给药的第5天至第18天,它们在统计学上无差异。这一发现与单剂量给药后观察到的终末半衰期相符,噻奈普汀为2.8±0.9小时,MC5代谢物为12.3±7小时。对于这两种化合物,稳态时血浆水平-时间曲线下面积与初始单剂量预测的结果一致,未显示出随时间的线性偏差。老年患者中噻奈普汀的药代动力学与年轻成年人报道的相似。然而,老年患者中MC5代谢物的血浆水平高于年轻患者。(摘要截短于250字)

相似文献

1
Pharmacokinetics of the antidepressant tianeptine at steady state in the elderly.抗抑郁药噻奈普汀在老年人稳态时的药代动力学
J Clin Pharmacol. 1991 Feb;31(2):174-8. doi: 10.1002/j.1552-4604.1991.tb03703.x.
2
The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration.抗抑郁药噻奈普汀及其主要代谢产物在健康人体内的药代动力学——酒精共同给药的影响
Fundam Clin Pharmacol. 1990;4(1):115-25. doi: 10.1111/j.1472-8206.1990.tb01021.x.
3
Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method.采用新型液相色谱串联质谱分析方法研究不同给药途径下硫醚哌嗪及其中间代谢产物 MC5 在大鼠体内的药代动力学。
Naunyn Schmiedebergs Arch Pharmacol. 2018 Feb;391(2):185-196. doi: 10.1007/s00210-017-1448-2. Epub 2017 Dec 12.
4
Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis.噻奈普汀及其主要代谢产物。在慢性肾衰竭和血液透析中的处置情况。
Fundam Clin Pharmacol. 1990;4(6):663-71. doi: 10.1111/j.1472-8206.1990.tb00046.x.
5
Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.噻奈普汀及其主要代谢产物在慢性酒精中毒和肝硬化中的药代动力学
Clin Pharmacokinet. 1989 Mar;16(3):186-91. doi: 10.2165/00003088-198916030-00005.
6
Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat.大鼠单次及长期腹腔注射后,天那普汀及其MC5代谢物在血浆、血液和大脑中的动力学特征。
Eur J Drug Metab Pharmacokinet. 1990 Jan-Mar;15(1):69-74. doi: 10.1007/BF03190130.
7
Influence of food on tianeptine and its main metabolite kinetics.食物对噻奈普汀及其主要代谢物动力学的影响。
J Clin Pharmacol. 1988 Dec;28(12):1115-9. doi: 10.1002/j.1552-4604.1988.tb05726.x.
8
Pharmacokinetic and bioequivalence assessment of two formulations of tianeptine sodium in healthy male volunteers.健康男性志愿者中两种硫蒽酮钠制剂的药代动力学和生物等效性评估。
Int J Clin Pharmacol Ther. 2014 Sep;52(9):817-23. doi: 10.5414/cp202128.
9
Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors.噻奈普汀在健康志愿者及有风险因素人群中的药代动力学和代谢参数。
Clin Neuropharmacol. 1988;11 Suppl 2:S90-6.
10
The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers.新型抗抑郁药噻奈普汀在健康志愿者体内的代谢途径。
Drug Metab Dispos. 1990 Sep-Oct;18(5):804-8.

引用本文的文献

1
Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3.抗抑郁药和抗精神病药与人体有机阳离子转运体 hOCT1、hOCT2 和 hOCT3 的相互作用。
Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1017-23. doi: 10.1007/s00210-012-0781-8. Epub 2012 Jul 18.
2
Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.塌陷反应介质蛋白-2:神经疾病适应证的新兴病理特征和治疗靶点。
Mol Neurobiol. 2011 Jun;43(3):180-91. doi: 10.1007/s12035-011-8166-4. Epub 2011 Jan 28.
3
Discriminative stimulus properties of tianeptine.
噻奈普汀的辨别刺激特性。
Psychopharmacology (Berl). 2006 Jan;183(4):446-51. doi: 10.1007/s00213-005-0210-5. Epub 2005 Nov 15.
4
Tianeptine: a review of its use in depressive disorders.噻奈普汀:用于抑郁症治疗的综述
CNS Drugs. 2001;15(3):231-59. doi: 10.2165/00023210-200115030-00006.
5
Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.新型抗抑郁药的代谢。药理学与药代动力学影响概述。
Clin Pharmacokinet. 1998 Apr;34(4):281-302. doi: 10.2165/00003088-199834040-00002.
6
Development of a population pharmacokinetic database for tianeptine.噻奈普汀群体药代动力学数据库的建立。
Eur J Clin Pharmacol. 1993;45(2):173-9. doi: 10.1007/BF00315502.
7
Pharmacokinetic optimisation of therapy with newer antidepressants.新型抗抑郁药治疗的药代动力学优化
Clin Pharmacokinet. 1994 Oct;27(4):307-30. doi: 10.2165/00003088-199427040-00005.
8
Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.噻奈普汀。对其药效学、药代动力学特性以及在抑郁症和并存的焦虑症与抑郁症中的治疗效果的综述。
Drugs. 1995 Mar;49(3):411-39. doi: 10.2165/00003495-199549030-00007.